This correlation would permit the use of CEA as a biomarker in NSCLC patients and would aid in identifying treatment candidates with reversible and irreversible EGFR-TKI resistance and candidates for whom an early intervention with combined chemotherapy and radiotherapy is more appropriate. Here, CEACAM5 is linked to non-small cell lung carcinoma.